University of Pittsburgh researchers have developed a novel class of anti-inflammatory agents: peptide-dragged mitochondria-targeted electron scavengers. These compounds are designed to target mitochondria and act as potent antioxidants, reducing excessive inflammation associated with various acute and chronic medical conditions such as sepsis, rheumatoid arthritis, and inflammatory bowel disease. This innovative approach offers a new mechanism of action for anti-inflammatory therapy.